Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK comparison of SB4 autoinjector vs pre-filled syringe in healthy males
NCT03193203Phase 1Completed
- Sponsor
- Samsung Bioepis
- Start
- Mar 2017
- Primary completion
- Aug 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of etanercept in rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and 2 more (2 arms), sponsored by Samsung Bioepis. Primary endpoints: Area under the concentration-time curve from time zero to infinity at 56 days, Area under the concentration-time curve from time zero to the last measurable concentration at 56 days and 1 more. Started Mar 2017; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)psoriatic arthritis (PsA)plaque psoriasisjuvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT03193203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193203.